Menu
The HeartFlow Analysis is a non-invasive personalized cardiac test that shows how each blockage impacts blood flow to your heart. We are committed to ensuring that the HeartFlow Analysis is affordable to everyone who needs the test. However, your insurance coverage, specific plan benefits and the type of facility you visit will determine if you owe anything for the test.
For a majority of patients, the HeartFlow Analysis will be billed through your insurance and provider; the HeartFlow Analysis is covered by Medicare and most commercial insurers. If you are a patient who is part of the HeartFlow Access Program, you may be responsible for paying HeartFlow directly for a portion of the test’s cost; our Patient Support Advisors can help guide you through the billing process and help answer any questions you have. Please read more details about the program below.
If you would like to receive a copy of your HeartFlow Analysis, please complete this form.
You may or may not be responsible for costs related to the HeartFlow Analysis depending on your insurance plan. HeartFlow’s Patient Support Advisors can help you find out if your health insurance plan covers the test and how much your out-of-pocket cost may be. They can also advise you if you qualify for any income-based payment programs. You also have the option to pay cash but will need to elect this option before the test is complete.
After the HeartFlow Analysis is completed, HeartFlow will send the claim to your insurance company and notify you that the claim was submitted.
Your insurance company will review the claim and send an Explanation of Benefits (EOB) to you. Please note that the EOB is not a bill. It is an informational summary of the claim.
You will receive a bill from HeartFlow if there is any amount owed after your insurance company has processed your claim. HeartFlow will submit any payment appeals on your behalf to ensure you owe the least amount necessary, but this final amount will vary based on your coverage.
The billing process takes time. You may not receive an EOB or a bill until several weeks or months after the HeartFlow Analysis is completed.
You can pay your bill using any of the below methods. We also offer cash-pay options, payment plans and low-cost options for those who qualify. Contact us for more details.
HeartFlow, Inc
PO Box 936258
Atlanta, GA 31192-6258
After reviewing your CCTA scan, your physician determined that more information was needed to properly diagnose your condition. The process is seamless for you, because it does not require an additional office visit. If you did not see your HeartFlow Analysis, you can request this from our support team using the form below. Many patients find their unique color-coded 3D model to be very informative. Here’s an example of what yours might look like and an example of the summary PDF you can request.
Our support team is ready to help you!
+1.877.HRT.FLOW | US
(+1.877.478.3569)
+44 (2) 38903267 | UK
The information provided by the HeartFlow Analysis is intended to be used in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement. The HeartFlow Analysis may not be appropriate for all patients. See indications for use for more information. The HeartFlow Analysis, featuring the FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States of America. The FFRCT Analysis and HeartFlow Planner are CE Marked in Europe and the United Kingdom and approved in Japan and Canada. The HeartFlow Analysis, featuring FFRCT Analysis, RoadMapTM Analysis, Plaque Analysis, and HeartFlow Planner, is commercially available in the United States. The FFRCT Analysis and HeartFlow Planner are commercially available in the United Kingdom. The FFRCT Analysis is also commercially available in Europe, Japan, and Canada.
© 2023 HeartFlow, Inc. | HeartFlow and the HeartFlow logo are registered trademarks of HeartFlow, Inc. Additionally, RoadMap is claimed as a trademark of HeartFlow, Inc. www.heartflow.com | 331 E Evelyn Ave, Mountain View, CA 94041
*Required fields
If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.
*Required fields
オンライン提出フォームから研究助成金を申請してください。
HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用することを目的としています。
ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.
さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.
The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.
For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.
If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.Please apply for research grants through our online submission form.
Executive Vice President and Chief Medical Officer
Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.
He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか？